Who can use Vesanoid(Cemiplimab)?

This section describes the approved use of VESANOID.

Therapeutic Indication

VESANOID is approved for the induction of remission in adult and pediatric patients (one year and older) with acute promyelocytic leukemia (APL) characterized by the presence of the t(15;17) translocation or PML/RARα gene expression. Its use is specifically for patients who are refractory to, have relapsed after anthracycline chemotherapy, or for whom anthracycline-based therapy is contraindicated.

Related Columns

Cemiplimab(Libtayo)

PD-1 inhibitor for advanced cutaneous squamous cell carcinoma, basal cell...

WeChat Scan
Free Inquiry

Indications for Cemiplimab

Cemiplimab is an important immunotherapeutic agent classified as a programmed death receptor-1 (PD-1) blocking antibody. As a significant breakthrough in the field of cancer immunotherapy in recent ye...

Indications of Cemiplimab

Cemiplimab is an important immunotherapeutic drug classified as a programmed death receptor-1 (PD-1) blocking antibody. As a major breakthrough in the field of cancer immunotherapy in recent years, th...

Indications of Cemiplimab

Cemiplimab is a programmed death receptor-1 (PD-1) blocking antibody that activates the immune system to fight against tumors by inhibiting the PD-1/PD-L1 pathway.Indications of CemiplimabCore Indicat...

Indications for Cemiplimab

Cemiplimab is an immune checkpoint inhibitor primarily used for treating specific types of skin cancer. It activates the patient's own immune system to attack tumor cells by blocking the PD-1 path...

Indications for Cemiplimab

Cemiplimab (trade name: LIBTAYO) is an innovative immunotherapeutic drug that activates the human immune system to fight tumors by targeting the PD-1 pathway.I. Indications for Cemiplimab1. Cutaneous ...